3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Cholangiocarcinoma
2
Upper Tract Urothelial Carcinomas
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Papillomavirus Infections
1
Oncogenic osteomalacia
1
Nasopharyngeal Neoplasms
1
Hypophosphatemia
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
14
fludarabine
10
fludarabine phosphate
8
Whole-Body Irradiation
7
thymoglobulin
5
Thiotepa
5
Tacrolimus
5
Stem Cell Transplantation
5
Standard of Care
5
Practice Guidelines as Topic
5
Nivolumab
5
Granulocyte Colony-Stimulating Factor
5
Busulfan
5
Azacitidine
5
venetoclax
4
Radiotherapy
4
Mycophenolic Acid
4
Methotrexate
4
Melphalan
4
Filgrastim
4
Cytarabine
4
Antilymphocyte Serum
4
Rituximab
3
Mesna
3
Leucovorin
3
Dexamethasone
3
Calcium Dobesilate
3
Alemtuzumab
3
ruxolitinib
2
ceritinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hematologic Neoplasms
×
infigratinib
×
Clear all
NCT02160041
2019-06-18
CBGJ398XUS04
Novartis
Phase 2
Terminated
84 enrolled
15 charts